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Abstract
Growing evidence has revealed high expression levels of stanniocalcin-1 (STC1) in differ-
ent types of human cancers. Numerous experimental studies using cancer cell lines demon-
strated the involvement of STC1 in inflammatory and apoptotic processes; however the role
of STC1 in carcinogenesis remains elusive. Hepatocellular carcinoma (HCC) an exempli-
fied model of inflammation-related cancer, represents a paradigm of studying the associa-
tion between STC1 and tumor development. Therefore, we conducted a statistical analysis
on the expression levels of STC1 using clinicopathological data from 216 HCC patients. We
found that STC1 was upregulated in the tumor tissues and its expression levels was posi-
tively correlated with the levels of interleukin (IL)-6 and IL-8. Intriguingly tumors with greater
expression levels of STC1 (tumor/normal 2) were significantly smaller than the lower level
(tumor/normal<2) samples (p = 0.008). A pharmacological approach was implemented to
reveal the functional correlation between STC1 and the ILs in the HCC cell-lines. IL-6 and
IL-8 treatment of Hep3B cells induced STC1 expression. Lentiviral-based STC1 overex-
pression in Hep3B and MHCC-97L cells however showed inhibitory action on the pro-migra-
tory effects of IL-6 and IL-8 and reduced size of tumor spheroids. The inhibitory effect of
STC1 on tumor growth was confirmed in vivo using the stable STC1-overexpressing 97L
cells on a mouse xenograft model. Genetic analysis of the xenografts derived from the
STC1-overexpressing 97L cells, showed upregulation of the pro-apoptotic genes interleu-
kin-12 and NOD-like receptor family, pyrin domain-containing 3. Collectively, the anti-
inflammatory and pro-apoptotic functions of STC1 were suggested to relate its inhibitory
effect on the growth of HCC cells. This study supports the notion that STC1 may be a poten-
tial therapeutic target for inflammatory tumors in HCC patients.
Introduction
Stanniocalcin-1 (STC1) is a hypocalcemic hormone, synthesized and secreted by a unique
endocrine gland, corpuscles of Stannius (CS) in bony fish. There is no CS gland or any compa-
rable structure found in mammals, the STC1 gene was believed to have been lost in evolution.
The mammalian forms of STC1, however, were cloned in gene-screening experiments using
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differential mRNA expression in mouse cDNA and human expressed sequence tag samples [1–
3], and was then found to be broadly expressed in various body tissues [4]. Early studies
intended to mirror the fish data and to validate the endocrine effects of STC1 on Ca2+ homeo-
stasis in mammals. However many studies illustrated the mammalian STC1 exerts its
functions via paracrine/autocrine pathways [5], which is different from the action reported in
fish models. In addition, a study using STC1 (-/-) null mice revealed that STC1 is not much
involved in blood Ca2+-regulation in mammals [6]. Unexpectedly, considerable studies
reported the involvement of the mammalian STC1 in processes of inflammation and carcino-
genesis [7].
In clinicopathological study of STC1 functions, significant elevated STC1 expression levels
were mostly detected in different human cancer samples, such as tumors of lung, breast, ovary,
colon, pancreas, and liver [7]. The elevated expression levels of STC1 identified in patients with
different cancer types was found to correlate to poor prognosis; hence, the use of STC1 as a
molecular marker for cancer progression has been suggested [7, 8]. In experimental studies of
analyzing STC1 functions, the use of nude mice xenograft models to study growth and metasta-
sis of different tumor cells, however has produced inconclusive results. Experimental studies
using ovarian [9], gastric [10], and colorectal [11] tumor cells in nude mice supported the pro-
oncogenic role of STC1. In another study, an anti-oncogenic role of STC1 via inhibiting prolif-
eration and invasion of cervical cancer cells was reported [12]. Accompanied with clinical anal-
ysis and nude mice studies, experimental investigations using human cancer cell lines
identified various transcriptional factors that regulated STC1 expression in the process of
tumor progression. For example, hypoxia-inducible factor (HIF)-1α [13, 14], p53 [15], Sp1
[16], RET-multiple endocrine neoplasia type 2B mutant protein [17], BRCA1 [18], and vascu-
lar endothelial growth factor (VEGF) [19–23] were shown to stimulate STC1 expression.
Although the underlying mechanistic actions of STC1 on tumor progression are not immedi-
ately obvious, a considerable number of experimental studies using different cancer cell lines
demonstrated that STC1 was involved in Warburg effect, apoptosis, angiogenesis, and wound
healing [14, 24–26]. Mitochondrial proteins (e.g., uncoupling factor 2) [27] and/or IL-6 [28]
were reported to be involved in the regulation or function of STC1, suggesting that STC1 may
participate in the modulation of mitochondrial antioxidant functions and cellular/tissue
inflammatory responses [29]. Despite the current evidence shows an association between STC1
and cancer progression, further investigation is necessary to reveal at the mechanistic perspec-
tives of its actions and effects on carcinogenesis.
Hepatocellular carcinoma (HCC) is the seventh most common cancer worldwide and the
third most common cause of death from cancer worldwide. HCC development is mainly due
to chronic inflammation and is therefore considered as an inflammatory cancer [30]. The
chronic inflammation is characterized by the continued expression of cytokines and recruit-
ment of immune cells to the liver, where the interaction with tumor cells is recognized to be
crucial for HCC development [31]. STC1 was found to be involved in inflammatory events [28,
29, 32] and was expressed in hepatocarcinomatous tissues [33, 34]; however, the role of STC1
in HCC progression is not known. In this study, clinicopathological and microarray profiling
data of paired tumor and adjacent normal tissues from 216 HCC patients were analyzed.
Experimental studies using various HCC cell-lines and nude mice xenograft model were con-
ducted to reveal the roles of STC1 in HCC progression. Our data suggested that STC1 inhibited
pro-migratory effects of IL6/IL8 and enable apoptotic pathways in tumor cells to reduce
growth and metastasis of HCC.
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Materials and Methods
Patient cohorts and clinical samples for microarray analysis
All patients enrolled in this study underwent a curative hepatectomy for HCC at Queen Mary
Hospital, Pokfulam, Hong Kong, between 1993 and 2007. The Institutional Review Board for
Human Ethics, The University of Hong Kong/Hospital Authority Hong Kong West Cluster
approved the study on the collection of clinical specimen for research. Written informed con-
sent was obtained from patients regarding the use of the liver specimens for research. The par-
ticipant consent forms were filed in the tissue bank in the Department of Surgery, The
University of Hong Kong. The samples were screened by microarray analysis as described pre-
viously [35]. Statistical analyses were conducted by GraphPad Prism 6 (GraphPad Software
Inc., La Jolla, CA) or SPSS 16.0 for Windows (SPSS, Chicago, IL). Pearson’s chi-squared test
and Student’s t-test were used for calculating the p-value, which was defined as statistically sig-
nificant at P< 0.05.
RNA, protein extraction, western blotting and quantitative PCR
Total RNA from cell lines, frozen patient samples, and xenografts was extracted using TRIzol
reagent according to the manufacturer’s instruction (Life Technologies, Carlsbad, CA). Five
hundred nanograms of patient RNA was reverse transcribed to cDNA using TaqMan Reverse
Transcription Kits (Applied Biosystems, Foster City, CA) while RNA of cell lines was reverse
transcribed using HC RNA-cDNAMaster Mix (Applied Biosystems). Quantitative PCR
(qPCR) was performed using Fast SYBR Green Master Mix (Applied Biosystems). The primer
sequences for STC1, IL-6, IL-8, IL-12A, IL-12B, NLRP3 and β-actin were as follows: STC1:
5’-TGAGGCGGAGCAGAATGACT-3’ and 5’-CAGGTGGAGTTTTCCAGGCAT-3’; IL6: 5’-
AGCCCACCGGGAACGAAAGA-3’ and 5’-TGTGTGGGGCGGCTAC ATCT-3’; IL8: 5’-
AAGCCACCGGAGCACTCCAT-3’ and 5’-CACGGCCAGCTTG GAAGTCA-3’; IL12A: 5’-
GAATGCAAAGCTTCTGATGGA-3’ and 5’-tcaaggga ggatttttgtgg-3’; IL12B: 5’-
ccctgacattctgcgttca-3’ and 5’–aggtc ttgtccgtgaagactcta-3’; NLRP3:
5’-TGAAGAGGAGTGGATGGGTT-3’ and 5’-GTCGTGTGTAGCGTTTGTTG-3’ and β-
actin: 5’-GACTACCTCATGAAGA TCCTCACC-3’ and 5’-TCTCCTTAATGTCACGCAC
GATT-3’. The thermocycling protocol was, 95°C for 1 min, followed by 40 cycles of 95°C for
10 s, 56°C for 10 s and 72°C for 30 s using the ABI StepOne Real-time PCR System (Applied
Biosystems).
For western blotting, protein lysates were prepared using RIPA buffer (50 mM Tris-HCl,
pH 7.4, 150 mMNaCl, 2mM EDTA, 1% NP-40, 0.1% SDS), supplemented with complete pro-
tease and PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche Life Sciences, Mannheim,
Germany). Protein concentrations were determined using the DC Protein Assay Kit II (Bio-
Rad, Hercules, CA). Proteins lysates were resolved by SDS-PAGE gels and were blotted as
described previously [13]. Blotting was conducted using mouse antibody against V5 (Invitro-
gen, Carlsbad, CA), rabbit antibodies against human STC1 (Origene, Rockville, MD), p-ERK1/
2, total-ERK1/2 (both from Cell Signaling Technology, Danvers, MA), anti-actin (Sigma-
Aldrich, St. Louis, MO), goat antibodies against human IL-6 or human IL-8 (R&D Systems,
Minneapolis, MN), followed by an incubation with horseradish peroxidase (HRP)-conjugated
goat anti-mouse/rabbit antibody (1:4000, BioRad, Hercules, CA, USA). Protein bands were
visualized using the chemiluminescent reagent (WestSave Up, AbFrontier, Seoul, South
Korea).
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Cell culture
Immortalized human hepatocyte MIHA, primary HCC (HepG2, Hep3B, HuH7, and H2P),
and metastatic HCC (MHCC-97L, MHCC-97H, H2M) cell lines were cultured in high-glucose
Dulbecco’s modified Eagle’s media (Life Technologies) supplemented with antibiotics (50 U/
mL penicillin and 50 μg/mL streptomycin) (Life Technologies), 10% heat-inactivated fetal
bovine serum (FBS) (HyClone; Life Technologies) and seeded overnight before treatments.
The human embryonic kidney cell line HEK293FT (Life Technologies) was cultured in the
same medium, supplemented with 6mM L-glutamine (Sigma-Aldrich) and 1 mM sodium
pyruvate (Sigma-Aldrich). Cells were serum starved overnight before an addition of recombi-
nant IL-6 and IL-8 (R&D Systems).
The basal levels of STC1 protein in cell lysates and conditioned cell culture media were mea-
sured by an enzyme-linked immunosorbent assay (ELISA), using the DuoSet ELISA kit (R&D
Systems), according to the manufacturer’s instruction. Briefly, wells of microplates were coated
with goat anti-human STC1 antibody at room temperature overnight, followed by blocking
with the reagent diluent (phosphate-buffered saline (PBS) containing 1% bovine serum albu-
min). Either samples or diluted STC1 standard solutions (62.5–4000 pg/mL) were added into
the antibody-coated wells, followed by an incubation with the biotinylated goat anti-human
STC1 antibody and streptavidin-HRP. After the addition of the substrates H2O2 and tetra-
methylbenzidine (TMB) (R&D Systems), the reaction was stopped using one molar H2SO4.
The absorbance at 450 nm was determined using an ELx800 microplate reader (BioTek,
Winooski, VT).
Overexpression of STC1
Construction of pLenti6.3/TO/V5-DEST-STC1 plasmid. Human STC1 cDNA encoding
the wild-type full-length protein without the stop codon was amplified by PCR and cloned into
pENTR/SD/D-TOPO (Life Technologies) according to the manufacturer’s instruction. The
STC1 insert was then cut from pENTR/SD/D-TOPO and cloned into the expression vector
pLenti6.3/TO/V5/-DEST (Life Technologies) using Gateway LR Clonase II Plus Enzyme Mix
(Life Technologies).
Production of lentivirus in 293FT and lentiviral overexpression of STC1 in Hep3B or
MHCC-97L cells. Overexpression of STC1 was established using a ViraPower Lentiviral
Expression System (Life Technologies) and conducted as described in our previous study [25].
Briefly, HEK293FT cells were seeded into 100-mm dishes overnight, then cotransfected with
ViraPower Packaging Mix and pLenti6.3/TO/V5-DEST-STC1 or pLenti6.3/TO/V5-DEST
using Lipofectamine 2000. Viral supernatants were harvested at 48 h after the transfection and
were immediately used or stored at −80°C. Hep3B or MHCC-97L cells were seeded at 1 × 105
cells/well into 6-well plates overnight, and then transduced with 1mL of lentiviral particles
with 6 μg/mL of polybrene (Sigma-Aldrich) for 24 h. Stable cell lines were selected under 4 μg/
mL blasticidin (Life Technologies) treatment over 2 weeks. Overexpression of STC1 in Hep3B
cells (Hep3B/STC1) or MHCC-97L cells (97L/STC1) was established in parallel with
pLenti6.3/TO/V5-DEST overexpression in Hep3B (Hep3B/pLenti) or in MHCC-97L (97L/
pLenti). The expression level of STC1 was confirmed by qPCR and western blotting.
Spheroid formation assay
A spheroid formation assay was performed using Costar 24-well clear, flat-bottom, ultra-low
attachment microplates (Corning, Corning, NY). Cell suspensions (2 × 103/well) were dis-
pensed into the plate with serum-free culture medium supplemented with 20ng/mL h-EGF
(Sigma-Aldrich), h-IGF and hFGF (both from Cell Signaling Technologies). Every 2–3 days,
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200 μL of fresh supplements were added into each well. After 10 days of incubation, tumor
spheroids were imaged and measured under a microscope at 200× magnification (Motic Asia,
Hong Kong).
Boyden chamber-based cell migration assay
Migration assays were performed using 24-well Transwell inserts with 8-μm pore size mem-
branes (Costar, Corning). Stably transduced Hep3B cells were trypsinized and washed twice
with serum-free medium. Then, the cells (6 × 104) were seeded into inserts (upper chamber)
with or without interleukins, while the complete medium was added at the lower chamber as
chemoattractant. After 24-h incubation at 37°C, the cells on the top of the insert membrane
were removed by cotton swabs and the cells at the bottom (migrated cells) were rinsed with
PBS, fixed with methanol for 10 min at −20°C, and stained with 0.5% Crystal Violet (Farco
Chemical Supplies). The total number of migrated cells was counted using microscopy and cell
morphology was captured at 100× magnification.
Measurement of secreted IL-6 and IL-8 by ELISA
The secretion of IL-6 and IL-8 was detected by the human ELISA kits, according to the manu-
facturer’s instruction (ExCell, Shanghai, China). Briefly, 100 μL of standards, samples, or dilu-
ents were added into each well and incubated for 90 min at 37°C. Then the wells were rinsed
with wash buffer 4 times, followed by an addition of 100 μL diluted biotinylated antibodies to
the wells (except the blank) and incubated for 60 min at 37°C. The wells were washed and
100 μL of diluted HRP-conjugated secondary antibody was added to the wells (except the
blank) and incubated for 30 min at 37°C. After the washing step, 100 μL of TMB substrate was
added into the wells and incubated for 15 min at 37°C. Following the incubation, 100 μL of
Stop Solution was added into the wells and absorbance was measured at 450 nm against the
background signal at 690 nm using the ELx800plate reader.
Xenograft animal tumor model
Animal experiments were approved by the Animals (Control of Experiments) Ordinance 340,
Hong Kong, and were conducted according to the guidelines of the Committee on the Use of
Live Animals in Teaching and Research (CULATR), The University of Hong Kong, Hong
Kong (Ref: 2825–12). Two hundred microliters of 97L/pLenti or 97L/STC1 cells (3 × 106) were
inoculated subcutaneously in the right flank of 6–7 week-old male mice (BALB-c nude)
(n = 10) using 29-gauge needles. Tumor volumes were measured every week and calculated by
a standard equation [(width2×length)/2]. When the mean tumor volume of 97L/pLenti-inocu-
lated mice reached approximately 700 mm3, all mice were sacrificed by anaesthetizing with
pentobarbital followed by cervical dislocation. The xenograft tumors in nude mice was dis-
sected and examined using hematoxylin-eosin staining. Levels of STC1 mRNA were measured
using real-time PCR (data not shown). Data are shown as means ± SEM. A p value of<0.05
was considered statistically significant. All studies were performed in duplicate for two inde-
pendent sets of the experiments.
Statistical analysis
All in vitro assays were analyzed by Student’s t-test or one-way analysis of variance (ANOVA)
followed by Duncan’s multiple range test. All data are shown as means ± SD. A p-value
of< 0.05 was considered statistically significant. All studies were performed in duplicate for
three independent sets of experiments.
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Results
Using a cohort of patients with HCC (n = 216), the STC1 gene expression level was examined
in paired HCC normal (N) and tumor (TU) tissues by microarray. To describe the high and
normal expression levels of STC1 in the patient samples, a ratio of TU/N 2 was defined to
denote high expression (STC1-High) whereas a ratio< 2 indicated low or normal expression
(STC1-Normal). Using these criteria, 40% of the cases were classified as STC1-High (85 cases
out of 216), and 60% of the cases were STC1-Normal (131 cases out of 216) (Table 1). Tumor
size of the cohort with STC1-High (mean 6.359) versus STC1-Normal (mean 7.841) was signif-
icantly reduced (p = 0.008), which was not associated with sex, age, tumor size with 5-cm cut-
off, alpha fetoprotein level, hepatitis B surface-antigen level, metastasis stage, histological
differentiation, infiltration, recurrence, and cirrhosis (Table 1). Indeed, the cohort with
STC1-High was not correlated with prolonged survival (S1 Fig). Expression of STC1 was deter-
mined in tumor-normal tissue paired samples using both microarray and qPCR. The microar-
ray data showed that the expression of STC1mRNA was increased by 1.49-fold in tumor
tissues (mean 7.023) as compared with their normal counterparts (mean 4.728) (p<0.0001, Fig
1A). To confirm the gene expression data from microarray, qPCR was performed using 38
tumor-normal paired samples. Consistent with the microarray data, the expression levels of
STC1 in tumor tissues was greater than the corresponding normal tissues (2.89-foldincrease,
p<0.05; Fig 1B). We then attempted to establish a correlation between STC1 with two well-
characterized cytokines, IL-6 and IL-8, among HCC cases. In the analysis of the clinicopatho-
logical data, STC1 expression level was found to be positively associated with IL-6 (p<0.0001)
and IL-8 (p = 0.0004) in HCC tumors using Pearson’s correlation analysis (Table 2).
To characterize the role of STC1 in hepatocarcinogenesis, expression levels of STC1 in dif-
ferent human HCC cell lines were determined and in vitro functional assays were then con-
ducted. The data revealed that low STC1 expression levels was detected in most of the HCC
cell lines, but the expression level was greater in H2P cells (Fig 2A). Consistently, the data of
ELISA showed significant high levels of STC1 protein detected in cell lysates and condition
media of H2P cells (Fig 2B). To compare the expression of profiles of STC1, IL6, IL8 and
pERK, protein lysates were prepared from Hep3B and H2P cells. H2P cells showed greater
expression levels of IL-6, IL-8 and p-ERK1/2 (137F5) (Fig 2C). The western blot data of IL6
and IL8 support the correlation analysis of the clinicopathological data from the patient sam-
ples (Table 2) and the findings reported by Westerberg et al. [28], showing STC1 expression
was induced by IL-6 via MAPK signaling. To investigate the possible cause-and-effect relation-
ship between STC1 and the cytokines IL6 and IL8, a pharmacological approach was adopted to
elucidate the possible interaction between IL-6, IL-8 and STC1 using Hep3B cells. Upon stimu-
lation by 50 ng/mL of IL-6 or IL-8 for 30 min, STC1 protein expression was found to be upre-
gulated (Fig 2D). On the contrary, to address the effects of STC1 on IL6/IL8 expression,
STC1-overexpressed Hep3B cells (Hep3B/STC1) and the empty vector control Hep3B/pLenti
were generated using lentiviral system. The overexpression of STC1 was verified using qPCR
(data not shown) and western blotting (Figure A in S2 File). The STC1-overexpressing cells,
either cultured in monolayers (Fig 2E) or spheroids (Fig 2F) condition, did not show noticeable
effects on the secretion (left) and mRNA expression (right) of IL-6 or IL-8. Collectively, the
data suggest that STC1 is a downstream target of IL6/IL8 in Hep3B cells.
To characterize the observation of the STC1-High cohort with shrinkage of tumor size, an
in vitro spheroid formation assay was implemented. Consistent with the clinicopathological
data, the size of the tumor spheroids of Hep3B/STC1 cells cultured for 10 days, was signifi-
cantly smaller (1.53-fold, p<0.01) than the spheroids of Hep3B/pLenti (Fig 3A). The viability
of Hep3B/STC1 cells was significantly reduced after 3 days of the incubation, as determined by
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MTT proliferation assay (Figure B in S2 File). Since the expression of STC1 was positively cor-
related to the levels of IL6 and IL8 in HCC tumors, whereas IL-6 and IL-8 is known to exert
pro-carcinogenic effects in HCC [36], the effect of STC1 on IL-6- or IL-8-elicited cell migration
was investigated using HCC cell-lines. In the control cells (Hep3B/pLenti), both IL-6 or IL-8
enhanced cell migration by 1.35- or 1.83-fold, respectively, versus the vehicle treatment
(p<0.05, Fig 3B). While the percentage of migration in STC1-overexpressed cells (Hep3B/
Table 1. The comparison of STC1 expression levels with clinicopathological data in HCC patients. HCC cases (n = 216) was divided into 2 cohorts,
STC1 high (STC1-High, TU/N2) and STC1 low or normal group (STC1-Normal, TN/N <2). Tumors with STC1-High were found to associate with smaller
size tumors. Chi-squared test was used to calculate the significance among different parameters. p<0.05 was considered as significant (n = 216).
Variables Frequency (%) STC1-Normal STC1-High P-value
Sex
Male 170 (78.7) 102 68 0.737
Female 46 (21.3) 29 17
Age
<60 131 (60.6) 79 52 1
60 85 (39.4) 52 33
Tumor size (cm)
<5 87 (40.3) 47 40 0.119
5 129 (59.7) 84 45
Alpha fetoprotein (ng/mL)
<250 126 (58.3) 76 50 1
250 90 (41.7) 55 35
Hepatitis B surface antigen*
Negative 30 (14) 21 9 0.317
Positive 185 (86) 110 75
Pathological tumor-node-metastasis stage
Early (I, II) 101 (46.8) 60 41 0.781
Late (III, IV) 115 (53.2) 71 44
Histological differentiation*
Well 37 (19.8) 22 15 0.71
Moderate/Poor 150 (80.2) 94 56
Venous inﬁltration
Absent 109 (50.5) 66 43 1
Present 107 (49.5) 65 42
Recurrence
Absent 99 (45.8) 57 42 0.406
Present 117 (54.2) 74 43
Cirrhosis*
Negative 208 (96.7) 127 81 0.438
Positive 7 (3.3) 3 4
Tumor size (cm)
Mean 7.841 6.359 0.008
SD 4.32 3.75
Number of tumor nodules
Mean 2.27 2.16 0.77
SD 2.77 2.65
*Incomplete patient information.
doi:10.1371/journal.pone.0139977.t001
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STC1) was similar to the Hep3B/pLenti cells. However the pro-migratory effects of IL-6 or IL-
8 were suppressed in the Hep3B/STC1 cells by 1.96- or 1.83-fold, respectively (p<0.0001, Fig
3B). To confirm the finding, another HCC cell line MHCC-97L (97L) with low basal STC1
expression was used. Stable overexpression of STC1 in 97L cells versus empty vector transduc-
tion was verified using qPCR (data not shown) and western blotting (Fig 3C, right). In 97L/
STC1 cells, the size of the tumor spheroids, after 10 days of incubation was 1.28-fold smaller
than the 97L/pLenti (p<0.05) (Fig 3C). Cell migratory activity was stimulated by IL-6 or IL-8
in the control cells (97L/pLenti) by 2.06- or 2.47-fold, respectively (p<0.001, Fig 3D), while the
pro-migratory effects of IL6 or IL8 were suppressed by STC1-overexpression in 97L/STC1 by
1.84- or 1.47-fold, respectively (p<0.0001, Fig 3D).
To validate the in vitro data, nude mice xenograft model was used. We firstly attempted to
inoculate Hep3B/STC1 or Hep3B/pLenti cells into nude mice, but no tumor growth was
observed with either cell line (data not shown). Therefore 97L cell-line was used for the inocu-
lation as it was successfully established in our previous study [37]. 97L/STC1 or 97L/pLenti
cells were subcutaneously inoculated into nude mice (n = 10), and the animals were then
Fig 1. STC1 was upregulated in HCC tumor tissues. STC1 gene expression level was detected and measured in both tumor (TU) and normal (N) patient
samples by using microarray analysis (A) and qPCR (B). STC1 gene expression was significantly greater in the TU samples vs normal tissues.
doi:10.1371/journal.pone.0139977.g001
Table 2. Expression level of STC1was correlated with IL6 and IL8 in HCC tumors (n = 220) using Pear-
son’s correlation analysis.
STC1
Parameter IL6-TU IL8-TU
Number of XY Pairs 220 220
Pearson r 0.2937 0.2352
95% conﬁdence interval 0.1679 to 0.4101 0.1062 to 0.3564
P-value (two-tailed) <0.0001 0.0004
P-value summary *** ***
Is the correlation signiﬁcant? (alpha = 0.05) Yes Yes
R square 0.08625 0.05531
doi:10.1371/journal.pone.0139977.t002
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Fig 2. STC1 was a downstream target of IL6 and IL8. (A) STC1 gene expression was determined in a panel of HCC cell lines using qPCR. (B) STC1
protein levels in cell lysates and condition media of H2P and Hep3B cells were measured using ELISA. (C) Western blotting analysis of STC1, IL6, IL8 and
ERK1/2 in H2P and Hep3B cell lines. (D) After overnight serum starvation, addition of 25 and 50 ng/ml of IL6 or IL8 in Hep3B cells for 30 min induced STC1
protein expression. The secretion (left) and gene expression (right) of both IL6 and IL8 were measured in Hep3Bmonolayer attached cells (E) and 10 days’
spheroids (F).
doi:10.1371/journal.pone.0139977.g002
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Fig 3. STC1 suppressed HCC tumor growth in vitro. Spheroid formation and cell migration assay were performed in both stably STC1-overexpressed
Hep3B (A-B) and 97L cell lines (C-D). The sizes of spheroids were measured at 10 days of the incubation. At least 3 random fields representing 200
spheroids were counted under 200x magnification. (A) In Hep3B cells, the representative pictures of spheroids were shown (top). (C) In 97L cells,
overexpression of STC1 was confirmed by probing with V5 antibody (right). Significant reductions in sizes of the spheroids in Hep3B/STC1 and 97L/STC1
were noted. * p<0.05, **p<0.01, compared with empty vector transduced cells. Bars = 50 μm. The activities of cell migration in transwells were induced in (B)
Hep3B cells and (D) 97L cells by the treatment with 50ng/ml of IL6 or IL8 for 24h. At least 5 random fields were counted under 100x magnification. The pro-
migratory effects of IL6 or IL8 on Hep3B/STC1 and 97L/STC1 were significantly suppressed by STC1-overexpression. * p<0.05, ** p<0.001, compared with
the treatments in the respective pLenti-transduced cells; # p<0.00001, compared with the same treatment group.
doi:10.1371/journal.pone.0139977.g003
STC1 Reduces Tumor Size in HCC
PLOSONE | DOI:10.1371/journal.pone.0139977 October 15, 2015 10 / 17
monitored every 3 days. Tumor sizes were measured weekly starting from 4 weeks of the inocu-
lation. Of the 10 mice injected with 97L cells, 100% developed tumors within 5 weeks of the
injection. Starting from 24 days of the inoculation, the size of xenograft tumors in 97L/
STC1-treated group was found to be significantly smaller than the 97L/pLenti-treated group
(p<0.05, Fig 4A). On the day of harvest (day 47), the tumors in the 97L/STC1-treated group
were about 70% smaller than those in the 97L/pLenti-treated group (p<0.005, Fig 4A). A repre-
sentative image is shown in Fig 4B. In parallel, the average tumor weight from the 97L/
STC1-treated group was ~70% smaller than that in the 97L/pLenti-treated group (p< 0.05);
the representative tumor masses are shown in Fig 4C, (top). We attempted to delineate the pos-
sible factors that might be involved in STC1-mediated reduction in tumor size. Total RNAs
were extracted from the xenografts and pro-apoptotic genes related to inflammation such as
interleukin-12 (IL12A and B) and NOD-like receptor family, pyrin domain containing 3
(NLRP3) were measured using qPCR,. IL12A, IL12B, and NLRP3 were found to be upregulated
by 1.75-, 2.68- and 3.81-fold, respectively, in 97L/STC1 xenografts as compared with the 97L/
pLenti xenografts (p<0.05, p<0.0001, Fig 4D).
Discussion
Current evidence suggests that STC1 plays roles in inflammation and carcinogenesis, but the
underlying mechanistic actions of STC1 remains unclear. Since HCC is an exemplified model
of inflammation-related cancer, it represents a paradigm of studying the association between
STC1 and tumor development. In the present study, STC1 was found to be highly expressed in
tumor tissues versus the adjacent normal counterpart, collected from the HCC cases. The
expression of STC1 was found to be positively associated with the levels of IL6 and IL8. The
greater expression levels of STC1 in tumor tissues have been reported in other types of cancers
[7, 33, 38, 39], however the functional correlation between STC1, IL6 and IL8 expression is not
clear. Experimental studies reported that STC1 regulates endothelial function via inhibiting
function of tumor necrotic factor (TNF)-α in cardiovascular inflammation [40] and counter-
acted lipopolysaccharide (LPS)-induced inflammatory cascade in lungs [41]. Anti-inflamma-
tory action of STC1 on endothelial cells and macrophages was reported [29] and was
demonstrated in a model of anti-glomerular basement membrane disease in STC1-transgenic
mice [32]. On the other hand, IL6 and IL8 are pro-inflammatory cytokines associated with
high inflammatory reaction in HCC while the elevated secretion of IL6 and IL8 in HCC is
known to promote metastasis and correlates with poor prognostic outcomes [42–46]. Intrigu-
ingly the STC1-High cohort was found to be an independent prognostic factor for overall sur-
vival among 216 HCC cases (S1 File). The observation is dissimilar to other type of cancer
cases (i.e. human esophageal squamous cell carcinoma, colorectal carcinoma, and leukemia), in
which STC1 was recognized as an unfavorable prognostic factor for post-operative outcome in
patients [47–49]. Therefore, it is interesting to determine the roles of STC1 on the effects of
pro-inflammatory cytokine on carcinogenesis of HCC.
With respect to tumor size analysis using the clinical data, the cohort of STC1-High showed
smaller size as compared to the STC1-low group, but this was found only in large tumors
(>6.3cm in diameter). This observation is agreeably to the fact that STC1 expression was
induced in hypoxia, which occurs in large solid tumors [14]. STC1 is a target gene of hypoxia-
inducible factor, which via gene transactivation by HIF-1α and/or IL-6-signaling [13, 14, 28].
Although the greater expression levels of STC1 in tumor samples could be interpreted as its
pro-oncogenic role in tumor progression, the counteracting effects STC1 on the pro-inflamma-
tory effects of IL6 and IL8 might slow down the process of carcinogenesis. This assumption is
supported by our in vitro HCC cell-line studies in which STC1 inhibited the pro-migratory
STC1 Reduces Tumor Size in HCC
PLOSONE | DOI:10.1371/journal.pone.0139977 October 15, 2015 11 / 17
Fig 4. STC1 suppressed HCC tumor growth in vivo. The transduced MHCC-97L cells [pLenti (97L/pLenti) or STC1 (97L/STC1)] were inoculated in nude
mice subcutaneously. (A) Tumor sizes were measured from 4 weeks of the inoculation (mean ± SEM). * p<0.05 and ** p<0.01, as compared with the 97L/
pLenti group. (B) The mice were scarified (10 mice per group) on 47 days after the inoculation and representative mice were shown. (C) Tumor xenografts
were dissected and weighted (mean ± SD), and the representative tumor masses were shown on top. Bar = 1cm. *, p<0.01, compared with the 97L/pLenti
group. (D) The expression levels of selected pro-apoptotic genes in xenograft samples were measured using qPCR. * p<0.05 and ** p<0.0001, compared
with the 97L/pLenti group.
doi:10.1371/journal.pone.0139977.g004
STC1 Reduces Tumor Size in HCC
PLOSONE | DOI:10.1371/journal.pone.0139977 October 15, 2015 12 / 17
effects of IL6 and IL8, and reduced sizes of tumor spheroids. Moreover, the xenograft animal
model in which STC1-overexpressing 97L cells grew slower than the control cells further rein-
forces this notion. Nonetheless, the underlying mechanism on how STC-1 reduced tumor
growth has not been revealed in this study. In the fact that growth-related function of STC1
was suggested in related to the pro- or anti-apoptotic effects of STC1 [7]. The anti-apoptotic
effect of STC1 was reported in different cell models, including thapsigargin-treated Paju cells
[50], hypoxia-induced lung cancer cells [51], and in human ovarian cancer cells [9]. Yet the
pro-apoptotic effects of STC1 were demonstrated in cultured chondrocytes [52], oxidative
stress-induced human nasopharyngeal cancer cells [15], trichostatin A treated human colorec-
tal cancer cells [53] and in oxidative stressed mouse embryo fibroblasts [54]. Therefore both
the anti-inflammatory and pro-apoptotic action of STC1 might reduce the growth of HCC
cells in vitro and in vivo. To address the possible mechanisms of STC1-driven tumor suppres-
sion, the expression of some inflammatory and pro-apoptotic genes in 97L/STC1- and 97L/
pLenti-derived tumor xenografts was measured and compared. We found that IL12 (isoforms
A and B) and NLRP3 were upregulated in 97L/STC1-derived tumor xenografts. Both IL-12 and
NLRP3 were reported to show antitumor effects on HCC progression [55, 56], and IL-12 was
shown to induce the production of cytokines to promote apoptosis [55]. The NLRP3 is the
most characterized inflammasome, acting as a danger signal sensor to initiate
inflammation through recruitment of caspases [56]. The pro-apoptotic effect of STC1 was fur-
ther noted in the condition of the HCC patients classified with both STC1-High and IL-
6-High/IL-8-High (S1 Table). Particularly, a significant reduction in tumor sizes was shown in
STC1/IL-8-High tumor (31% reduction versus STC1/IL-8-Normal, p = 0.025), but not in
STC1/IL-6-High cases (22% reduction versus STC1/IL-6-Normal, p = 0.245), which may due
to the small sample size of the STC1/IL-6-High cohort. Therefore, it warrants conducting a
further large-scale study using well-characterized HCC patient samples with high expression
levels of STC1, IL-6 and IL-8. Collectively, our data are the first to demonstrate that
the suppressive effect of STC1 on HCC tumors is associated with the inflammatory
milieu.
Supporting Information
S1 Fig. An overall survival curves according to STC1 gene expression levels.Overall survival
curve for high (green) and normal/low (blue) expression of STC1 in HCC patients (n = 216) by
Kaplan-Meier analysis. The cohort with STC1-High was not correlated to prolong survival in
HCC.
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was verified in Hep3B cell line using V5 antibody (Figure A). Cell viability of Hep3B/STC1
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(PDF)
S2 File. ARRIVE guidelines checklist.
(DOC)
S1 Table. Clinicopathological data on tumor size among HCC samples with different
expression levels of STC1, IL6 and IL8. p<0.05 was considered as significant.
(PDF)
STC1 Reduces Tumor Size in HCC
PLOSONE | DOI:10.1371/journal.pone.0139977 October 15, 2015 13 / 17
Acknowledgments
The authors thank Tak Chan and Dodo Lam for the technical support in the animal
experiment.
Author Contributions
Conceived and designed the experiments: CKCW BHYY. Performed the experiments: BHYY.
Analyzed the data: BHYY CKCW FHS NPL. Contributed reagents/materials/analysis tools:
CKCWNPL. Wrote the paper: CKCW BHYY.
References
1. Chang AC, DunhamMA, Jeffrey KJ, Reddel RR. Molecular cloning and characterization of mouse stan-
niocalcin cDNA. Mol Cell Endocrinol. 1996; 124(1–2):185–7. Epub 1996/11/29. PMID: 9027337.
2. Chang AC, Janosi J, Hulsbeek M, de Jong D, Jeffrey KJ, Noble JR, et al. A novel human cDNA highly
homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol. 1995; 112(2):241–7. Epub 1995/
08/11. PMID: 7489828.
3. Olsen HS, Cepeda MA, Zhang QQ, Rosen CA, Vozzolo BL. Human stanniocalcin: a possible hormonal
regulator of mineral metabolism. Proc Natl Acad Sci U S A. 1996; 93(5):1792–6. Epub 1996/03/05.
PMID: 8700837; PubMed Central PMCID: PMC39860.
4. Varghese R, Wong CK, Deol H, Wagner GF, DiMattia GE. Comparative analysis of mammalian stan-
niocalcin genes. Endocrinology. 1998; 139(11):4714–25. Epub 1998/10/30. PMID: 9794484.
5. Yoshiko Y, Aubin JE. Stanniocalcin 1 as a pleiotropic factor in mammals. Peptides. 2004; 25(10):1663–
9. doi: 10.1016/j.peptides.2004.04.015 PMID: 15476933.
6. Chang AC, Hook J, Lemckert FA, McDonald MM, Nguyen MA, Hardeman EC, et al. The murine stan-
niocalcin 2 gene is a negative regulator of postnatal growth. Endocrinology. 2008; 149(5):2403–10. doi:
10.1210/en.2007-1219 PMID: 18258678.
7. Yeung BH, Law AY, Wong CK. Evolution and roles of stanniocalcin. Mol Cell Endocrinol. 2012; 349
(2):272–80. Epub 2011/11/26. doi: 10.1016/j.mce.2011.11.007 PMID: 22115958.
8. Chang AC, Jellinek DA, Reddel RR. Mammalian stanniocalcins and cancer. Endocr Relat Cancer.
2003; 10(3):359–73. Epub 2003/09/25. PMID: 14503913.
9. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, et al. Stanniocalcin 1 and ovarian tumori-
genesis. J Natl Cancer Inst. 2010; 102(11):812–27. Epub 2010/05/21. doi: djq127 [pii] doi: 10.1093/jnci/
djq127 PMID: 20484106; PubMed Central PMCID: PMC2879417.
10. He LF, Wang TT, Gao QY, Zhao GF, Huang YH, Yu LK, et al. Stanniocalcin-1 promotes tumor angio-
genesis through up-regulation of VEGF in gastric cancer cells. J Biomed Sci. 2011; 18(1):39. Epub
2011/06/16. doi: 10.1186/1423-0127-18-39 PMID: 21672207.
11. Pena C, Cespedes MV, Lindh MB, Kiflemariam S, Mezheyeuski A, Edqvist PH, et al. STC1 expression
by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer research. 2013; 73
(4):1287–97. doi: 10.1158/0008-5472.CAN-12-1875 PMID: 23243022.
12. Guo F, Li Y, Wang J, Li Y, Li Y, Li G. Stanniocalcin1 (STC1) Inhibits Cell Proliferation and Invasion of
Cervical Cancer Cells. PloS one. 2013; 8(1):e53989. doi: 10.1371/journal.pone.0053989 PMID:
23382863; PubMed Central PMCID: PMC3558422.
13. Law AYS, Ching LY, Lai KP, Wong CKC. Identification and characterization of the hypoxia-responsive
element in human stanniocalcin-1 gene. Mol Cell Endocrinol. 2010; 314(1):118–27. doi: 10.1016/j.mce.
2009.07.007 ISI:000272101700014. PMID: 19628018
14. Yeung HY, Lai KP, Chan HY, Mak NK, Wagner GF, Wong CKC. Hypoxia-inducible factor-1-mediated
activation of stanniocalcin-1 in human cancer cells. Endocrinology. 2005; 146(11):4951–60. doi: 10.
1210/En.2005-0365 PMID: 16109785.
15. Lai KP, Law AY, Yeung HY, Lee LS, Wagner GF, Wong CK. Induction of stanniocalcin-1 expression in
apoptotic human nasopharyngeal cancer cells by p53. Biochem Biophys Res Commun. 2007; 356
(4):968–75. Epub 2007/03/31. doi: 10.1016/j.bbrc.2007.03.074 PMID: 17395153.
16. Law AY, Yeung B, Ching L, Wong CK. Sp1 is a transcription repressor to stanniocalcin-1 expression in
TSA-treated human colon cancer cells, HT29. Journal of Cellular Biochemistry. 2011. Epub 2011/04/
06. doi: 10.1002/jcb.23127 PMID: 21465530.
17. Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, Nagasaka T, et al. Characterization
of gene expression induced by RET with MEN2A or MEN2Bmutation. Am J Pathol. 2002; 161(1):249–
56. doi: 10.1016/S0002-9440(10)64176-4 PMID: 12107109; PubMed Central PMCID: PMC1850689.
STC1 Reduces Tumor Size in HCC
PLOSONE | DOI:10.1371/journal.pone.0139977 October 15, 2015 14 / 17
18. Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, et al. BRCA1
transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci U S A. 2002; 99
(11):7560–5. doi: 10.1073/pnas.062181799 PMID: 12032322; PubMed Central PMCID: PMC124283.
19. Bell SE, Mavila A, Salazar R, Bayless KJ, Kanagala S, Maxwell SA, et al. Differential gene expression
during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in
basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein sig-
naling. Journal of cell science. 2001; 114(Pt 15):2755–73. PMID: 11683410.
20. Jauhiainen S, Hakkinen SK, Toivanen PI, Heinonen SE, Jyrkkanen HK, Kansanen E, et al. Vascular
Endothelial Growth Factor (VEGF)-D Stimulates VEGF-A, Stanniocalcin-1, and Neuropilin-2 and Has
Potent Angiogenic Effects. Arterioscler Thromb Vasc Biol. 2011. Epub 2011/04/09. doi: ATV-
BAHA.111.225961 [pii] doi: 10.1161/ATVBAHA.111.225961 PMID: 21474827.
21. Kahn J, Mehraban F, Ingle G, Xin X, Bryant JE, Vehar G, et al. Gene expression profiling in an in vitro
model of angiogenesis. Am J Pathol. 2000; 156(6):1887–900. doi: 10.1016/S0002-9440(10)65062-6
PMID: 10854212; PubMed Central PMCID: PMC1850089.
22. Liu D, Jia H, Holmes DI, Stannard A, Zachary I. Vascular endothelial growth factor-regulated gene
expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors
Nur77, Nurr1, and Nor1. Arterioscler Thromb Vasc Biol. 2003; 23(11):2002–7. doi: 10.1161/01.ATV.
0000098644.03153.6F PMID: 14525795.
23. Wary KK, Thakker GD, Humtsoe JO, Yang J. Analysis of VEGF-responsive genes involved in the acti-
vation of endothelial cells. Molecular cancer. 2003; 2:25. doi: 10.1186/1476-4598-2-25 PMID:
12904264; PubMed Central PMCID: PMC179881.
24. Yeung BH, Wong CK. Stanniocalcin-1 regulates re-epithelialization in human keratinocytes. PloS one.
2011; 6(11):e27094. Epub 2011/11/10. doi: 10.1371/journal.pone.0027094 PMID: 22069492; PubMed
Central PMCID: PMC3206080.
25. Law AY, Wong CK. Stanniocalcin-1 and -2 promote angiogenic sprouting in HUVECs via VEGF/
VEGFR2 and angiopoietin signaling pathways. Mol Cell Endocrinol. 2013; 374(1–2):73–81. doi: 10.
1016/j.mce.2013.04.024 PMID: 23664860.
26. Ohkouchi S, Block GJ, Katsha AM, Kanehira M, Ebina M, Kikuchi T, et al. Mesenchymal Stromal Cells
Protect Cancer Cells From ROS-induced Apoptosis and Enhance the Warburg Effect by Secreting
STC1. Mol Ther. 2011. Epub 2011/12/08. doi: 10.1038/mt.2011.259 PMID: 22146344.
27. Wang Y, Huang L, Abdelrahim M, Cai Q, Truong A, Bick R, et al. Stanniocalcin-1 suppresses superox-
ide generation in macrophages through induction of mitochondrial UCP2. J Leukoc Biol. 2009; 86
(4):981–8. Epub 2009/07/16. doi: 10.1189/jlb.0708454 PMID: 19602668; PubMed Central PMCID:
PMC2752019.
28. Westberg JA, Serlachius M, Lankila P, PenkowaM, Hidalgo J, Andersson LC. Hypoxic preconditioning
induces neuroprotective stanniocalcin-1 in brain via IL-6 signaling. Stroke. 2007; 38(3):1025–30. doi:
10.1161/01.Str.0000258113.67252.Fa PMID: 17272771.
29. Sheikh-Hamad D. Mammalian stanniocalcin-1 activates mitochondrial antioxidant pathways: new para-
digms for regulation of macrophages and endothelium. Am J Physiol Renal Physiol. 2010; 298(2):
F248–54. Epub 2009/08/07. doi: 10.1152/ajprenal.00260.2009 PMID: 19656913.
30. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nature reviews Gastroenterology &
hepatology. 2010; 7(8):448–58. doi: 10.1038/nrgastro.2010.100 PMID: 20628345.
31. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, et al. The inflammatory
microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages.
BioMed research international. 2013; 2013:187204. doi: 10.1155/2013/187204 PMID: 23533994;
PubMed Central PMCID: PMC3591180.
32. Huang L, Garcia G, Lou Y, Zhou Q, Truong LD, DiMattia G, et al. Anti-inflammatory and renal protective
actions of stanniocalcin-1 in a model of anti-glomerular basement membrane glomerulonephritis. Am J
Pathol. 2009; 174(4):1368–78. Epub 2009/02/28. doi: 10.2353/ajpath.2009.080476 PMID: 19246645;
PubMed Central PMCID: PMC2671368.
33. Fujiwara Y, Sugita Y, Nakamori S, Miyamoto A, Shiozaki K, Nagano H, et al. Assessment of Stanniocal-
cin-1 mRNA as a molecular marker for micrometastases of various human cancers. Int J Oncol. 2000;
16(4):799–804. Epub 2000/03/16. PMID: 10717250.
34. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, et al. Genome-wide analysis of gene
expression in human hepatocellular carcinomas using cDNAmicroarray: identification of genes
involved in viral carcinogenesis and tumor progression. Cancer research. 2001; 61(5):2129–37. PMID:
11280777.
35. Lee NP, Tsang FH, Shek FH, Mao M, Dai H, Zhang C, et al. Prognostic significance and therapeutic
potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. International
STC1 Reduces Tumor Size in HCC
PLOSONE | DOI:10.1371/journal.pone.0139977 October 15, 2015 15 / 17
journal of cancer Journal international du cancer. 2010; 127(4):968–76. doi: 10.1002/ijc.25100 PMID:
19998337.
36. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible
involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. Journal of gastroenterol-
ogy. 1994; 29(4):423–9. PMID: 7951851.
37. Wang Y, Shek FH, Wong KF, Liu LX, Zhang XQ, Yuan Y, et al. Anti-cadherin-17 antibody modulates
beta-catenin signaling and tumorigenicity of hepatocellular carcinoma. PloS one. 2013; 8(9):e72386.
doi: 10.1371/journal.pone.0072386 PMID: 24039755; PubMed Central PMCID: PMC3770615.
38. Arigami T, Uenosono Y, Ishigami S, Hagihara T, Haraguchi N, Matsushita D, et al. Expression of stan-
niocalcin 1 as a potential biomarker of gastric cancer. Oncology. 2012; 83(3):158–64. Epub 2012/08/
15. doi: 10.1159/000341390 PMID: 22889960.
39. ShirakawaM, Fujiwara Y, Sugita Y, Moon JH, Takiguchi S, Nakajim K, et al. Assessment of stanniocal-
cin-1 as a prognostic marker in human esophageal. Oncol Rep. 2011. Epub 2011/12/28. doi: 10.3892/
or.2011.1607 PMID: 22200953.
40. Chen CY, Jamaluddin MS, Yan SY, Sheikh-Hamad D, Yao QZ. Human stanniocalcin-1 blocks TNF-
alpha-induced monolayer permeability in human coronary artery endothelial cells. Arterioscl Throm
Vas. 2008; 28(5):906–12. doi: 10.1161/Atvbaha.108.163667 PMID: 18309109.
41. Tang SE, Wu CP, Wu SY, Peng CK, PerngWC, Kang BH, et al. Stanniocalcin-1 ameliorates lipopoly-
saccharide-induced pulmonary oxidative stress, inflammation, and apoptosis in mice. Free radical biol-
ogy & medicine. 2014; 71:321–31. doi: 10.1016/j.freeradbiomed.2014.03.034 PMID: 24685991.
42. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that
activates neutrophils. The Journal of clinical investigation. 1989; 84(4):1045–9. doi: 10.1172/
JCI114265 PMID: 2677047; PubMed Central PMCID: PMC329758.
43. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed
tissues and outcome in hepatocellular carcinoma. The New England journal of medicine. 2008; 359
(19):1995–2004. doi: 10.1056/NEJMoa0804525 PMID: 18923165; PubMed Central PMCID:
PMC2963075.
44. Kubo F, Ueno S, Hiwatashi K, Sakoda M, Kawaida K, Nuruki K, et al. Interleukin 8 in human hepatocel-
lular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Annals
of surgical oncology. 2005; 12(10):800–7. doi: 10.1245/ASO.2005.07.015 PMID: 16132378.
45. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic
liver diseases. Gastroenterology. 1992; 103(1):264–74. PMID: 1612333.
46. Xie Y, ShengW, Xiang J, Ye Z, Yang J. Interleukin-17F suppresses hepatocarcinoma cell growth via
inhibition of tumor angiogenesis. Cancer investigation. 2010; 28(6):598–607. doi: 10.3109/
07357900903287030 PMID: 20210523.
47. Song H, Xu B, Yi J. Clinical significance of stanniocalcin-1 detected in peripheral blood and bone mar-
row of esophageal squamous cell carcinoma patients. Journal of experimental & clinical cancer
research: CR. 2012; 31(1):35. Epub 2012/04/28. doi: 10.1186/1756-9966-31-35 PMID: 22537917.
48. Tamura S, Oshima T, Yoshihara K, Kanazawa A, Yamada T, Inagaki D, et al. Clinical Significance of
STC1 Gene Expression in Patients with Colorectal Cancer. Anticancer Res. 2011; 31(1):325–9. Epub
2011/01/29. doi: 31/1/325 [pii]. PMID: 21273618.
49. Tohmiya Y, Koide Y, Fujimaki S, Harigae H, Funato T, Kaku M, et al. Stanniocalcin-1 as a novel marker
to detect minimal residual disease of human leukemia. Tohoku J Exp Med. 2004; 204(2):125–33.
PMID: 15383693.
50. Zhang K, Lindsberg PJ, Tatlisumak T, Kaste M, Olsen HS, Andersson LC. Stanniocalcin: A molecular
guard of neurons during cerebral ischemia. Proc Natl Acad Sci U S A. 2000; 97(7):3637–42. doi: 10.
1073/pnas.070045897 PMID: 10725397; PubMed Central PMCID: PMC16292.
51. Block GJ, Ohkouchi S, Fung F, Frenkel J, Gregory C, Pochampally R, et al. Multipotent stromal cells
are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem cells.
2009; 27(3):670–81. doi: 10.1002/stem.20080742 PMID: 19267325.
52. Wu S, Yoshiko Y, De Luca F. Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogen-
esis. The Journal of biological chemistry. 2006; 281(8):5120–7. doi: 10.1074/jbc.M506667200 PMID:
16377640.
53. Law AY, Lai KP, Lui WC, Wan HT, Wong CK. Histone deacetylase inhibitor-induced cellular apoptosis
involves stanniocalcin-1 activation. Exp Cell Res. 2008; 314(16):2975–84. doi: 10.1016/j.yexcr.2008.
07.002 PMID: 18652825.
54. Nguyen A, Chang AC, Reddel RR. Stanniocalcin-1 acts in a negative feedback loop in the prosurvival
ERK1/2 signaling pathway during oxidative stress. Oncogene. 2009; 28(18):1982–92. doi: 10.1038/
onc.2009.65 PMID: 19347030.
STC1 Reduces Tumor Size in HCC
PLOSONE | DOI:10.1371/journal.pone.0139977 October 15, 2015 16 / 17
55. Komita H, Homma S, Saotome H, Zeniya M, Ohno T, Toda G. Interferon-gamma produced by interleu-
kin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carci-
noma. Journal of hepatology. 2006; 45(5):662–72. doi: 10.1016/j.jhep.2006.05.018 PMID: 16935390.
56. Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X, et al. Deregulation of the NLRP3 inflammasome in hepatic
parenchymal cells during liver cancer progression. Laboratory investigation; a journal of technical meth-
ods and pathology. 2014; 94(1):52–62. doi: 10.1038/labinvest.2013.126 PMID: 24166187.
STC1 Reduces Tumor Size in HCC
PLOSONE | DOI:10.1371/journal.pone.0139977 October 15, 2015 17 / 17
